Arabic Arabic English English French French German German
dark

Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

Alnylam Pharmaceuticals, Inc. announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

JPM Day 4: Battered Emergent Solutions Looks Ahead, Vir and Thermo Fisher

Next Post

2022 will see pharma target nutraceutical products to tap into consumer spending on preventative health

Related Posts
Total
0
Share